Skip to main content
. Author manuscript; available in PMC: 2021 Sep 27.
Published in final edited form as: J Bone Miner Res. 2021 May 5;36(8):1448–1458. doi: 10.1002/jbmr.4308

Figure 4. Receptor expression in osteoblasts and osteoclasts.

Figure 4.

Expression of glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-2 receptor (GLP-2R) in human osteoblast and osteoclasts. (A) analyses of GIPR and GLP-2R expression at different time points (day 0, 6, 12) during osteoblast differentiation of human mesenchymal stem cells (hMSC) and (B) analyses of GIPR and GLP-2R expression at different time points (36 h, 72 h, 96 h) during osteoclast differentiation of human osteoclast precursors treated with macrophage-colony stimulating factor MCSF-1 and receptor activator of nuclear κβ (RANKL). Actin beta (ACTB), lipoprotein lipase (LPL), alkaline phosphatase (ALPL), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), bone gamma-carboxyglutamate protein (BGLAP), and cathepsin K (CTSK) were used as housekeeping, negative-, and positive controls, respectively. (C) mRNA expression of GLP-2R, GIPR and cathepsin K (CTSK) (positive control) in primary mature human osteoclasts treated with MCSF and RANKL (n = 8). Each gene is normalized to gene length and the number of reads sequenced per sample (reads per kilobase million (RPKM)). (C) Data are shown asboxplot (with median, interquartile range, maximum, and minimum) showing all data points.